ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
,ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
,ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
, ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
1. A kwoman kdiagnosed kwith kobsessive–compulsive kdisorder khas kbeen kprescribed
koral k paroxetine khydrochloride. k What k is kthe kexpected keffect k for kthis
kprescription?
A. Curative keffect kon ksymptoms
B. Systemic keffect kon ksymptoms
C. Local keffect kon ksymptoms
D. Parenteral keffect kon ksymptoms
ANS: k kB
Rationale: kDrugs kthat kproduce ksystemic keffects kare ktaken kinto kthe kbody, kcirculated
kthrough k the kbloodstream kto ktheir ksites kof kaction kin kvarious kbody ktissues, kand
keventually keliminated k from kthe kbody. kCurative kagents kare kgiven kto k cure ka kdisease
kprocess. kIn kthis kcase, kparoxetine k hydrochloride kwill kcontrol kthe ksymptoms kbut k not kcure
kthe kdisorder. kDrugs kwith klocal keffects, k such kas ksunscreen kand klocal kanesthetics, kact
kmainly kat kthe ksite kof kapplication. k Paroxetine k hydrochloride k is knot kadministered
kparenterally. kParenteral kagents kare kadministered k subcutaneously, k intramuscularly, kor
kintravenously.
PTS: 1 REF: p. k3, kIntroduction OBJ: 1
NAT: k Client kNeeds: kPhysiological kIntegrity: kPharmacological kand kParenteral
kTherapies k TOP: Chapter: k1: kThe kFoundation kof kPharmacology: k Quality kand kSafety
KEY: k Integrated kProcess: kNursing kProcess
BLM: k k Cognitive kLevel: kUnderstand NOT: k Multiple kChoice
2. A kclient khas kbeen kprescribed kan kantibiotic. kThis kmedication kis ka knaturally koccurring
substance kthat khas kbeen kcheGmRicA
alDlyEm
SoBdOifOieSd.TWhaOt kM
.C is kanother kname kfor kthis ktype kof
kmedication?
A. Synthetic kdrug
B. Semisynthetic kdrug
C. Biotechnology kdrug
D. Prototype kdrug
ANS: k kB
Rationale: kSemisynthetic kdrugs k(e.g., kmany kantibiotics) kare k naturally koccurring ksubstances
k that khave kbeen kchemically kmodified. kSynthetic kdrugs kare kmore kstandardized k in ktheir
kchemical k characteristics, k more kconsistent k in ktheir keffects, kand kless klikely kto k produce
kallergic kreactions. k Biotechnology kdrugs kinvolve k manipulating kDNA kand kRNA kand
krecombining kgenes kinto k hybrid kmolecules kthat k can kbe kinserted kinto kliving korganisms.
kPrototype kdrugs kare kthe kfirst k drug kof ka kparticular kgroup kto k be kdeveloped.
PTS: 1 REF: p. k3, kDrug kSources OBJ: 1
NAT: k Client kNeeds: kPhysiological kIntegrity: kPharmacological kand kParenteral
kTherapies k TOP: Chapter: k1: kThe kFoundation kof kPharmacology: kQuality kand kSafety
KEY: k Integrated kProcess: kNursing kProcess
BLM: k k Cognitive kLevel: kUnderstand NOT: k Multiple kChoice
3. Which kclassification kapplies kto kmorphine?
A. Central knervous ksystem kdepressant
B. Central knervous ksystem kstimulant
ABRAMS' kCLINICAL kDRUG kTHERAPY: kRATIONALES kFOR kNURSING kPRACTICE
,ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
,ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
, ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
1. A kwoman kdiagnosed kwith kobsessive–compulsive kdisorder khas kbeen kprescribed
koral k paroxetine khydrochloride. k What k is kthe kexpected keffect k for kthis
kprescription?
A. Curative keffect kon ksymptoms
B. Systemic keffect kon ksymptoms
C. Local keffect kon ksymptoms
D. Parenteral keffect kon ksymptoms
ANS: k kB
Rationale: kDrugs kthat kproduce ksystemic keffects kare ktaken kinto kthe kbody, kcirculated
kthrough k the kbloodstream kto ktheir ksites kof kaction kin kvarious kbody ktissues, kand
keventually keliminated k from kthe kbody. kCurative kagents kare kgiven kto k cure ka kdisease
kprocess. kIn kthis kcase, kparoxetine k hydrochloride kwill kcontrol kthe ksymptoms kbut k not kcure
kthe kdisorder. kDrugs kwith klocal keffects, k such kas ksunscreen kand klocal kanesthetics, kact
kmainly kat kthe ksite kof kapplication. k Paroxetine k hydrochloride k is knot kadministered
kparenterally. kParenteral kagents kare kadministered k subcutaneously, k intramuscularly, kor
kintravenously.
PTS: 1 REF: p. k3, kIntroduction OBJ: 1
NAT: k Client kNeeds: kPhysiological kIntegrity: kPharmacological kand kParenteral
kTherapies k TOP: Chapter: k1: kThe kFoundation kof kPharmacology: k Quality kand kSafety
KEY: k Integrated kProcess: kNursing kProcess
BLM: k k Cognitive kLevel: kUnderstand NOT: k Multiple kChoice
2. A kclient khas kbeen kprescribed kan kantibiotic. kThis kmedication kis ka knaturally koccurring
substance kthat khas kbeen kcheGmRicA
alDlyEm
SoBdOifOieSd.TWhaOt kM
.C is kanother kname kfor kthis ktype kof
kmedication?
A. Synthetic kdrug
B. Semisynthetic kdrug
C. Biotechnology kdrug
D. Prototype kdrug
ANS: k kB
Rationale: kSemisynthetic kdrugs k(e.g., kmany kantibiotics) kare k naturally koccurring ksubstances
k that khave kbeen kchemically kmodified. kSynthetic kdrugs kare kmore kstandardized k in ktheir
kchemical k characteristics, k more kconsistent k in ktheir keffects, kand kless klikely kto k produce
kallergic kreactions. k Biotechnology kdrugs kinvolve k manipulating kDNA kand kRNA kand
krecombining kgenes kinto k hybrid kmolecules kthat k can kbe kinserted kinto kliving korganisms.
kPrototype kdrugs kare kthe kfirst k drug kof ka kparticular kgroup kto k be kdeveloped.
PTS: 1 REF: p. k3, kDrug kSources OBJ: 1
NAT: k Client kNeeds: kPhysiological kIntegrity: kPharmacological kand kParenteral
kTherapies k TOP: Chapter: k1: kThe kFoundation kof kPharmacology: kQuality kand kSafety
KEY: k Integrated kProcess: kNursing kProcess
BLM: k k Cognitive kLevel: kUnderstand NOT: k Multiple kChoice
3. Which kclassification kapplies kto kmorphine?
A. Central knervous ksystem kdepressant
B. Central knervous ksystem kstimulant
ABRAMS' kCLINICAL kDRUG kTHERAPY: kRATIONALES kFOR kNURSING kPRACTICE
